CN113730650B - Carbohydrate-lysozyme composition and preparation method and application thereof - Google Patents
Carbohydrate-lysozyme composition and preparation method and application thereof Download PDFInfo
- Publication number
- CN113730650B CN113730650B CN202111194181.2A CN202111194181A CN113730650B CN 113730650 B CN113730650 B CN 113730650B CN 202111194181 A CN202111194181 A CN 202111194181A CN 113730650 B CN113730650 B CN 113730650B
- Authority
- CN
- China
- Prior art keywords
- injection
- parts
- carbohydrate
- vitamin
- raw materials
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/02—Inorganic materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/06—Flowable or injectable implant compositions
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Dermatology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides a carbohydrate-lysozyme composition, a preparation method and application thereof, and relates to the technical field of injection medicines. A carbohydrate-lysozyme composition comprises the following raw materials in parts by volume: 4-7 parts of lidocaine injection, 8-12 parts of sodium bicarbonate injection, 1-3 parts of dexamethasone injection and 40-60 parts of physiological saline. The pharmaceutical composition provided by the invention can effectively stimulate the increase of the number of lipases in local fat cells and further stimulate the activation of protein, so that intracellular deoxyribo-triphosphate is converted into deoxyribo-glycine, the activation of fat is promoted to increase and cut off fatty acid, the fatty acid is decomposed into a fine state, the fatty acid is discharged from the body by a lymphatic system along with the metabolism of the body, and the moisture of skin cells can be locked, so that the nutritional ingredients of subcutaneous cells are supplied, and the activity of the subcutaneous cells is promoted, thereby relieving the states of fat accumulation, wrinkles and unevenness.
Description
Technical Field
The invention relates to the technical field of injection medicines, and particularly relates to a carbohydrate-lysozyme composition and a preparation method and application thereof.
Background
With the development of economic society, the pace of life is also increasing, and various stresses to which people are subjected are also steadily increasing, so that the balance of human metabolism may be disrupted, the supply of nutrients required by the skin tends to be slow, and the pigment blasts become active. In addition to the influence of external factors (such as strong ultraviolet irradiation or wrong use of cosmetics, etc.), the skin is easily roughened, dull, and even spotty. In addition, the human face has the following problems: developed masseter, rough facial lines, water retention, facial edema, fat accumulation, obvious cheek flesh sensation, loose skin, drooping cheek contours and the like.
The problem of edema, obesity or fat on the face causes serious troubles to the life of modern women. The problem of the female is solved by surgical fat suction, injection of a face thinning needle and the like, but the mode has extremely high risk and even endangers life; some women can exercise facial muscles to achieve the purpose of face slimming, but the method is hard to persist, and improper operation possibly causes excessive exercise of the facial muscles, so that another form of facial obesity is caused, and the operation is more difficult; the traditional Chinese medicine is taken orally to lose weight, but the traditional Chinese medicine generally acts on the whole body, and almost cannot be used for local face thinning, so that the effect is very little.
For loose wrinkles on the face, the theory is described as the reduction of collagen secretion and the natural aging relaxation, and for the condition of over-age and particularly severe skin relaxation, the condition can be relatively improved, but the ideal effect can not be completely achieved. In the prior art, facial skin is usually improved obviously in a short time after the facial mask is applied to the face by adopting modes such as facial mask application and the like aiming at facial skin relaxation and aging. For a facial mask product, the using effect mainly depends on the absorption efficiency of skin on nutrient components in the facial mask, and the existing facial mask has the defects that the absorption efficiency is not high after application, so that the nutrient components are lost.
Therefore, the research of researchers in this field is directed to develop a cosmetic drug with better efficacy against the problems of edema and heaviness of the middle face and loose wrinkles of the face, and a safe method of using the same.
Disclosure of Invention
The invention aims to provide a carbohydrate lysozyme composition which can effectively improve the conditions of facial fat overfilling and skin laxity.
It is another object of the present invention to provide a method for preparing a carbohydrate-lyase composition, which is simple in preparation scheme.
Another object of the present invention is to provide a use of a carbohydrate lysozyme composition in the field of facial cosmetics.
The technical problem to be solved by the invention is realized by adopting the following technical scheme.
In one aspect, the present application provides a carbohydrate-lysozyme composition, which includes the following raw materials in parts by volume: 4-7 parts of lidocaine injection, 8-12 parts of sodium bicarbonate injection, 1-3 parts of dexamethasone injection and 40-60 parts of physiological saline.
Furthermore, the raw materials also comprise 5-10 parts of compound gastrodine injection and 3-8 parts of levocarnitine injection.
Furthermore, the raw materials also comprise 15 to 25 parts of compound calcium carbonate injection, 0.8 to 1.2 parts of vitamin B1 injection, 0.8 to 1.4 parts of vitamin B6 injection and 0.6 to 1.5 parts of vitamin B12 injection.
In another aspect, the present embodiments provide a method for preparing a carbohydrate-lyase composition, which includes the following steps: weighing the raw materials according to the volume, mixing the raw materials except the normal saline, adding the normal saline while stirring, continuously stirring uniformly, subpackaging, sealing and sterilizing to obtain the carbohydrate-lysozyme composition.
In another aspect, the present invention provides a carbohydrate lysozyme injection prepared from the above carbohydrate lysozyme composition, and an application of the carbohydrate lysozyme injection in the field of facial beauty treatment.
Compared with the prior art, the embodiment of the invention has at least the following advantages or beneficial effects:
aiming at the condition of excessive facial fat filling, the pharmaceutical composition is compounded by lidocaine, sodium bicarbonate, dexamethasone, compound gastrodin, levocarnitine and normal saline, and the synergistic effect is exerted through local injection; the lidocaine injection has good surface penetrating power and anesthetic effect, and improves the injection effect; the sodium bicarbonate injection and the levocarnitine injection are matched to effectively stimulate the increase of the number of lipase in local fat cells, further stimulate the activation of protein, convert the deoxyribonuclein triphosphate in the cells into deoxyribonuclein acid, promote the activation of fat, increase and cut off the fatty acid, decompose the fatty acid into a fine state, and are matched with the compound gastrodin injection to dredge channels and promote circulation, the fat is discharged out of a human body from a lymphatic system along with the metabolism of the human body, and finally the dexamethasone injection is matched to diminish inflammation, inhibit immunity, comprehensively play the roles of relieving fat accumulation and reducing facial fat.
Aiming at the condition of facial skin relaxation, the invention adopts lidocaine, sodium bicarbonate, dexamethasone, compound calcium carbonate, vitamin B1, vitamin B6 and vitamin B12 for compound collocation, wherein the lidocaine injection has good surface penetration and anesthesia effect, and improves the injection effect; the compound calcium carbonate, the vitamin B1, the vitamin B6 and the vitamin B12 are adopted to lock the moisture of skin cells, supply the nutrition components to subcutaneous cells, promote the activity of the subcutaneous cells and the growth of the cells, so that the face skin is full, the wrinkle and the unevenness of the skin are relieved, and a new medicine combination selection is provided for clinical treatment.
Detailed Description
In order to make the objects, technical solutions and advantages of the embodiments of the present invention clearer, the technical solutions in the embodiments of the present invention will be clearly and completely described below. The examples, in which specific conditions are not specified, were conducted under conventional conditions or conditions recommended by the manufacturer. The reagents or instruments used are not indicated by the manufacturer, and are all conventional products available commercially.
It should be noted that, in the present application, the embodiments and features of the embodiments may be combined with each other without conflict. The present invention will be described in detail below with reference to specific examples.
A carbohydrate lytic enzyme composition comprising the following raw materials in parts by volume: 4-7 parts of lidocaine injection, 8-12 parts of sodium bicarbonate injection, 1-3 parts of dexamethasone injection and 40-60 parts of physiological saline.
In some embodiments of the present invention, the above-mentioned carbohydrate-lyase composition further comprises the following raw materials in parts by volume: 5-10 parts of compound gastrodine injection and 3-8 parts of levocarnitine injection.
In some embodiments of the present invention, the above-mentioned carbohydrate-lyase composition comprises the following parts by volume of the raw materials: 5 parts of lidocaine injection, 10 parts of sodium bicarbonate injection, 2 parts of dexamethasone injection, 8 parts of compound gastrodin injection, 5 parts of levocarnitine injection and 50 parts of normal saline.
In some embodiments of the present invention, the above-mentioned carbohydrate-lyase composition further comprises the following raw materials in parts by volume: 15-25 parts of compound calcium carbonate injection, 0.8-1.2 parts of vitamin B1 injection, 0.8-1.4 parts of vitamin B6 injection and 0.6-1.5 parts of vitamin B12 injection. The vitamin B1 injection is combined with pyrophosphoric acid in vivo to form a coacetidase which participates in the oxidative decarboxylation reaction of pyruvic acid and a-ketoglutaric acid in sugar metabolism and is necessary for sugar metabolism; the vitamin B6 injection is converted into pyridoxal phosphate in erythrocytes, and the pyridoxal phosphate is used as a coenzyme to play a role in various metabolic functions of protein, carbohydrate and lipid and also participate in the conversion of tryptophan into nicotinic acid or 5-hydroxytryptamine; the vitamin B12 injection is involved in methyl conversion and folic acid metabolism in vivo, and promotes the conversion of 5-methyltetrahydrofolic acid into tetrahydrofolic acid.
In some embodiments of the present invention, the above-mentioned carbohydrate-lyase composition comprises the following parts by volume of the raw materials: 5 parts of lidocaine injection, 10 parts of sodium bicarbonate injection, 2 parts of dexamethasone injection, 20 parts of compound calcium carbonate injection, 1 part of vitamin B1 injection, 1 part of vitamin B6 injection, 1 part of vitamin B12 injection and 50 parts of normal saline.
A method of preparing a carbohydrate lytic enzyme composition, comprising the steps of:
weighing the raw materials according to the volume, mixing the raw materials except the normal saline, adding the normal saline while stirring, continuously stirring uniformly, subpackaging, sealing by melting and sterilizing to obtain the carbohydrate-lysozyme composition.
In some embodiments of the present invention, the stirring time after the physiological saline is added is 10-30min.
In some embodiments of the present invention, the dispensing specifically comprises: the well-mixed liquid was dispensed into 1-2mL ampoules. 1-2mL of injection is injected each time, which is more beneficial to the absorption of skin cells.
The carbolysin injection prepared from the carbolysin composition and the application thereof in the field of facial beautification.
The features and properties of the present invention are described in further detail below with reference to examples.
Example 1
A carbohydrate lysozyme composition comprising the following raw materials: 5mL of lidocaine injection, 10mL of sodium bicarbonate injection, 2mL of dexamethasone injection and 50mL of normal saline.
Sequentially adding the lidocaine injection, the sodium bicarbonate injection and the dexamethasone injection into a container for mixing, adding the physiological saline while stirring after uniformly mixing, stirring for 20min under a sterile environment, subpackaging into 1mL ampoule bottles, and performing sealing and sterilization to obtain the carbohydrate-lysozyme injection.
And (3) extracting 1 ampoule of carbolysin injection as the acupoint injection, and selecting the part of the patient needing to be injected and filled for local injection.
Example 2
A carbohydrate lytic enzyme composition comprising the following raw materials: 4mL of lidocaine injection, 10mL of sodium bicarbonate injection, 2mL of dexamethasone injection and 60mL of physiological saline.
Sequentially adding the lidocaine injection, the sodium bicarbonate injection and the dexamethasone injection into a container for mixing, adding the physiological saline while stirring after uniformly mixing, stirring for 15min under a sterile environment, then subpackaging into 2mL ampoules, and carrying out melt sealing and sterilization to obtain the carbohydrate lysozyme injection.
And (3) extracting 1 ampoule of carbolysin injection as the acupoint injection, and selecting the part of the patient needing to be injected and filled for local injection.
Example 3
A carbohydrate lysozyme composition comprising the following raw materials: 7mL of lidocaine injection, 8mL of sodium bicarbonate injection, 3mL of dexamethasone injection and 40mL of normal saline.
Sequentially adding the lidocaine injection, the sodium bicarbonate injection and the dexamethasone injection into a container for mixing, adding the physiological saline while stirring after uniformly mixing, stirring for 20min under a sterile environment, subpackaging into 1mL ampoule bottles, and performing sealing and sterilization to obtain the carbohydrate-lysozyme injection.
And (3) extracting 1 ampoule of carbohydrate-lyase injection as an acupoint injection, and selecting a part to be injected and filled of a patient for local injection.
Example 4
A carbohydrate lytic enzyme composition comprising the following raw materials: 6mL of lidocaine injection, 12mL of sodium bicarbonate injection, 1mL of dexamethasone injection and 55mL of normal saline.
Sequentially adding the lidocaine injection, the sodium bicarbonate injection and the dexamethasone injection into a container for mixing, adding the physiological saline while stirring after uniformly mixing, stirring for 30min under a sterile environment, subpackaging into 1mL ampoule bottles, and performing sealing and sterilization to obtain the carbohydrate-lysozyme injection.
And (3) extracting 1 ampoule of carbolysin injection as the acupoint injection, and selecting the part of the patient needing to be injected and filled for local injection.
Example 5
A carbohydrate lysozyme composition comprising the following raw materials: 6mL of lidocaine injection, 12mL of sodium bicarbonate injection, 1mL of dexamethasone injection, 10mL of compound gastrodin injection, 3mL of levocarnitine injection and 55mL of normal saline.
Sequentially adding the lidocaine injection, the sodium bicarbonate injection, the dexamethasone injection, the compound gastrodin injection and the levocarnitine injection into a container for mixing, adding the physiological saline while stirring after uniformly mixing, stirring for 20min under a sterile environment, subpackaging in a 1mL ampoule bottle, and performing sealing and sterilization to obtain the carbohydrate lysozyme injection.
And (3) extracting 1 ampoule of carbolysin injection as the acupoint injection, and selecting the part of the patient needing to be injected and filled for local injection.
Example 6
A carbohydrate lysozyme composition comprising the following raw materials: 5mL of lidocaine injection, 12mL of sodium bicarbonate injection, 1.5mL of dexamethasone injection, 5mL of compound gastrodin injection, 8mL of levocarnitine injection and 45mL of normal saline.
Sequentially adding the lidocaine injection, the sodium bicarbonate injection, the dexamethasone injection, the compound gastrodine injection and the levocarnitine injection into a container for mixing, uniformly mixing, adding the physiological saline while stirring, stirring for 25min in a sterile environment, subpackaging in a 1mL ampoule bottle, and carrying out sealing and sterilization to obtain the carbohydrate lysozyme injection.
And (3) extracting 1 ampoule of carbolysin injection as the acupoint injection, and selecting the part of the patient needing to be injected and filled for local injection.
Example 7
A carbohydrate lytic enzyme composition comprising the following raw materials: 5mL of lidocaine injection, 10mL of sodium bicarbonate injection, 2mL of dexamethasone injection, 8mL of compound gastrodin injection, 5mL of levocarnitine injection and 50mL of normal saline.
Sequentially adding the lidocaine injection, the sodium bicarbonate injection, the dexamethasone injection, the compound gastrodin injection and the levocarnitine injection into a container for mixing, adding the physiological saline while stirring after uniformly mixing, stirring for 20min under a sterile environment, subpackaging in 2mL ampoule bottles, and performing sealing and sterilization to obtain the carbohydrate lysozyme injection.
And (3) extracting 1 ampoule of carbolysin injection as the acupoint injection, and selecting the part of the patient needing to be injected and filled for local injection.
Example 8
A carbohydrate lysozyme composition comprising the following raw materials: 6mL of lidocaine injection, 11mL of sodium bicarbonate injection, 2mL of dexamethasone injection, 15mL of compound calcium carbonate injection, 1.2mL of vitamin B1 injection, 0.8mL of vitamin B6 injection, 1.5mL of vitamin B12 injection and 55mL of normal saline.
Sequentially adding lidocaine injection, sodium bicarbonate injection, dexamethasone injection, compound calcium carbonate injection, vitamin B1 injection, vitamin B6 injection and vitamin B12 injection into a container for mixing, adding physiological saline while stirring after uniform mixing, stirring for 23min under a sterile environment, then subpackaging into a 1mL ampoule bottle, and obtaining the carbohydrate lysozyme injection of the embodiment after sealing and sterilization.
And (3) extracting 1 ampoule of carbolysin injection as the acupoint injection, and selecting the part of the patient needing to be injected and filled for local injection.
Example 9
A carbohydrate lysozyme composition comprising the following raw materials: 4mL of lidocaine injection, 11mL of sodium bicarbonate injection, 1mL of dexamethasone injection, 25mL of compound calcium carbonate injection, 0.8mL of vitamin B1 injection, 1.4mL of vitamin B6 injection, 0.6mL of vitamin B12 injection and 52mL of normal saline.
Sequentially adding lidocaine injection, sodium bicarbonate injection, dexamethasone injection, compound calcium carbonate injection, vitamin B1 injection, vitamin B6 injection and vitamin B12 injection into a container for mixing, adding physiological saline while stirring after uniform mixing, stirring for 20min under a sterile environment, then subpackaging into a 1mL ampoule bottle, and obtaining the carbohydrate lysozyme injection of the embodiment after sealing and sterilization.
And (3) extracting 1 ampoule of carbolysin injection as the acupoint injection, and selecting the part of the patient needing to be injected and filled for local injection.
Example 10
A carbohydrate lysozyme composition comprising the following raw materials: 5mL of lidocaine injection, 10mL of sodium bicarbonate injection, 2mL of dexamethasone injection, 20mL of compound calcium carbonate injection, 1mL of vitamin B1 injection, 1mL of vitamin B6 injection, 1mL of vitamin B12 injection and 50mL of normal saline.
Sequentially adding lidocaine injection, sodium bicarbonate injection, dexamethasone injection, compound calcium carbonate injection, vitamin B1 injection, vitamin B6 injection and vitamin B12 injection into a container for mixing, adding physiological saline while stirring after uniform mixing, stirring for 25min under a sterile environment, then subpackaging into a 1mL ampoule bottle, and obtaining the carbohydrate lysozyme injection of the embodiment after sealing and sterilization.
And (3) extracting 1 ampoule of carbohydrate-lyase injection as an acupoint injection, and selecting a part to be injected and filled of a patient for local injection.
Examples of the experiments
The effect of the carbolysin injection on facial fat accumulation was investigated.
In this experimental example, 239 patients with facial fat accumulation symptoms were selected from the group consisting of people who were collected between 11 and 2020-12 months in 2015, and treated in 11 groups, wherein experimental groups 1 to 10 were injected with the carbohydrase injection prepared in examples 1 to 10, and experimental group 11 was a blank group and was injected with physiological saline. The experimental groups 1-11 were injected with 1mL each time, 1 time per week for 4 consecutive weeks, each cycle was completed and the next cycle was started with a monthly interval, and the treatment time was 3 cycles. The treatment condition is counted after three cycles, wherein the facial fat accumulation symptom disappears to be cured, obvious improvement is changed into obvious effect, the effect improvement condition is general or no obvious improvement is changed into ineffective effect, the effective rate is counted, and the statistical result is shown in table 1. Effective rate = (number of cure people + number of significant effect people)/total number of people.
TABLE 1
As can be seen from Table 1, the carbohydrate lipase injection solutions prepared in the experimental groups 1 to 10 of the present invention have a very good therapeutic effect on the symptoms of fat accumulation compared to the experimental group 11, and particularly, the experimental groups 5 to 7 have the best effect in terms of both the effective rate and the cure rate, and the experimental groups 8 to 10 have decreased effects by adding other raw materials on the basis of the raw materials of the experimental groups 1 to 4.
Secondly, the effect of the carbolysin injection on facial relaxation is explored.
In this experimental example, 294 patients with facial flabby and wrinkled skin were selected from the group consisting of patients collected between 11 and 2021 in 2015, and divided into 11 groups for treatment, wherein the experimental groups 1-10 were injected with the carbohydrase injection prepared in examples 1-10, and the experimental group 11 was a blank group and was injected with physiological saline. The experimental groups 1-11 were injected with 1mL each time, 1 time per week for 4 consecutive weeks, each cycle was completed and the next cycle was started with a monthly interval, and the treatment time was 3 cycles. The treatment conditions are counted after three cycles, wherein the facial skin is loosened, wrinkles are obviously improved to be healed, better improvement is obvious, the effect improvement condition is general or no obvious improvement is ineffective, the effective rate is counted, and the statistical result is shown in table 2. Effective rate = (number of recovery people + number of significant effect)/total number of people.
TABLE 2
| Experimental group | Total number of people | The number of healed people | Number of effective people | Number of invalid persons | Effective rate of |
| 1 | 27 persons | 8 persons | 16 persons | 3 persons | 88.89％ |
| 2 | 26 persons | 10 persons | 14 persons | 2 persons | 92.31％ |
| 3 | 26 persons | 8 persons | 16 persons | 2 persons | 92.31％ |
| 4 | 26 persons | 9 persons | 16 persons | 1 person | 96.15％ |
| 5 | 26 persons | 8 persons | 14 persons | 4 persons | 84.62％ |
| 6 | 27 persons | 11 persons | 13 persons | 3 persons | 88.89％ |
| 7 | 27 persons | 9 persons | 15 persons | 3 persons | 88.89％ |
| 8 | 27 persons | 18 persons | 8 persons | 1 person | 96.30％ |
| 9 | 27 persons | 15 persons | 11 persons | 1 person | 96.30％ |
| 10 | 28 persons | 19 persons | 9 persons | 0 person | 100％ |
| 11 | 27 persons | 2 persons | 6 persons | 19 persons | 29.63％ |
As can be seen from Table 2, the carbolysin injections prepared in test groups 1-10 of the present invention showed very good therapeutic effects on the symptoms of facial skin laxity, especially the results of test groups 8-10 were the best in terms of both effective rate and cure rate, indicating that the lysin injections prepared in examples 8-10 are more suitable for patients with facial skin laxity.
In a typical proportion, dingzhi, age 55, facial laxity and strong lines affect the overall facial beauty, and after two weeks of treatment by using the medicine prepared in the embodiment 7 of the invention, the patient has improved remarkably and the wrinkle symptoms basically disappear by facial diagnosis.
In summary, the carbohydrate-soluble enzyme composition, the preparation method and the application thereof are provided in the embodiments of the present invention. Aiming at the condition of excessive facial fat filling, the pharmaceutical composition is compounded by lidocaine, sodium bicarbonate, dexamethasone, compound gastrodin, levocarnitine and normal saline, and the synergistic effect is exerted through local injection; the lidocaine injection has good surface penetrating power and anesthetic effect, and improves the injection effect; the sodium bicarbonate injection and the levocarnitine injection are matched to effectively stimulate the increase of the number of lipase in local fat cells, further stimulate the activation of protein, convert the deoxyribonuclein triphosphate in the cells into deoxyribonuclein acid, promote the activation of fat, increase and cut off the fatty acid, decompose the fatty acid into a fine state, and are matched with the compound gastrodin injection to dredge channels and promote circulation, the fat is discharged out of a human body from a lymphatic system along with the metabolism of the human body, and finally the dexamethasone injection is matched to diminish inflammation, inhibit immunity, comprehensively play the roles of relieving fat accumulation and reducing facial fat.
Aiming at the condition of facial skin relaxation, the invention adopts lidocaine, sodium bicarbonate, dexamethasone, compound calcium carbonate, vitamin B1, vitamin B6 and vitamin B12 to carry out compound collocation, wherein the lidocaine injection has good surface penetrating power and anesthetic effect, and the injection effect is improved; the compound calcium carbonate, the vitamin B1, the vitamin B6 and the vitamin B12 are adopted to lock the moisture of skin cells, supply the nutrition components to subcutaneous cells, promote the activity of the subcutaneous cells and promote the growth of the cells, thereby relieving the state of skin wrinkles and unevenness and providing a new medicine combination selection for clinical treatment.
The embodiments described above are some, but not all embodiments of the invention. The detailed description of the embodiments of the present invention is not intended to limit the scope of the invention as claimed, but is merely representative of selected embodiments of the invention. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
Claims (9)
1. A carbohydrate lysozyme composition, characterized in that it consists of the following parts by volume of raw materials when used for facial fat overfilling: 4-7 parts of lidocaine injection, 8-12 parts of sodium bicarbonate injection, 1-3 parts of dexamethasone injection, 40-60 parts of physiological saline, 5-10 parts of compound gastrodine injection and 3-8 parts of levocarnitine injection.
2. The carbohydrate lysozyme composition of claim 1, wherein the carbohydrate lysozyme composition comprises the following raw materials in parts by volume: 5 parts of lidocaine injection, 10 parts of sodium bicarbonate injection, 2 parts of dexamethasone injection, 8 parts of compound gastrodin injection, 5 parts of levocarnitine injection and 50 parts of normal saline.
3. A carbohydrate lytic enzyme composition which, when used for facial laxity, is composed of the following raw materials in parts by volume: 4-7 parts of lidocaine injection, 8-12 parts of sodium bicarbonate injection, 1-3 parts of dexamethasone injection, 40-60 parts of physiological saline, 15-25 parts of compound calcium carbonate injection, 0.8-1.2 parts of vitamin B1 injection, 0.8-1.4 parts of vitamin B6 injection and 0.6-1.5 parts of vitamin B12 injection.
4. A carbohydrate lysozyme composition according to claim 3, wherein the carbohydrate lysozyme composition is comprised of the following raw materials in parts by volume: 5 parts of lidocaine injection, 10 parts of sodium bicarbonate injection, 2 parts of dexamethasone injection, 20 parts of compound calcium carbonate injection, 1 part of vitamin B1 injection, 1 part of vitamin B6 injection, 1 part of vitamin B12 injection and 50 parts of normal saline.
5. A process according to any one of claims 1 to 4, comprising the steps of:
weighing the raw materials according to the volume, mixing the raw materials except the normal saline, adding the normal saline while stirring, continuously stirring uniformly, subpackaging, sealing and sterilizing to obtain the carbohydrate-lysozyme composition.
6. The method of claim 5, wherein the physiological saline is added with stirring for 10-30min.
7. The method for preparing a carbohydrate-containing lysozyme composition according to claim 5, wherein the dispensing comprises the following steps: the well mixed liquid is dispensed into 1-2mL ampoules.
8. A carbohydrate lysin injection prepared by using a carbohydrate lysin composition according to any one of claims 1-4.
9. Use of the carbolysin injection according to claim 8 for the preparation of a material for the cosmetic field of the face.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111194181.2A CN113730650B (en) | 2021-10-13 | 2021-10-13 | Carbohydrate-lysozyme composition and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111194181.2A CN113730650B (en) | 2021-10-13 | 2021-10-13 | Carbohydrate-lysozyme composition and preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113730650A CN113730650A (en) | 2021-12-03 |
| CN113730650B true CN113730650B (en) | 2022-11-01 |
Family
ID=78726594
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111194181.2A Active CN113730650B (en) | 2021-10-13 | 2021-10-13 | Carbohydrate-lysozyme composition and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113730650B (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1650919A (en) * | 2004-12-10 | 2005-08-10 | 山东齐都药业有限公司 | Prescription of Chinese medicine compound preparation, its preparation method and use |
| CN102940623A (en) * | 2012-12-05 | 2013-02-27 | 罗诚 | Medicinal composition of levocarnitine compound |
| CA2967699A1 (en) * | 2014-11-13 | 2016-05-19 | Merz Pharma Gmbh & Co. Kgaa | Dermal filler based on crosslinked hyaluronic acid and carboxymethyl cellulose lubricant |
| WO2017037593A2 (en) * | 2015-08-28 | 2017-03-09 | 康霈生技股份有限公司 | Pharmaceutical composition used for reducing localised fat and use of pharmaceutical composition |
| CN110604834A (en) * | 2019-03-14 | 2019-12-24 | 上海欧邦医疗管理有限公司 | Application of hydro-acupuncture liquid medicine in preparation of medicine for treating lymph stasis and obstruction areas |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101506204B1 (en) * | 2014-01-13 | 2015-03-27 | 김삼 | Medicine Composition Reinforcing Botox Function and Comprising Fat Decompostion Function |
| CN105534783A (en) * | 2015-12-29 | 2016-05-04 | 杭州芭黎雅医疗美容诊所有限公司 | Autologous collagen baby-face-preserving composition and method for preparing composition |
| KR101706549B1 (en) * | 2016-09-09 | 2017-02-14 | 손유나 | Injection composition comprising hyaluronidase for Local Fat Reduction |
| CN106377542A (en) * | 2016-11-11 | 2017-02-08 | 上海俏佳人医疗美容门诊部股份有限公司 | Local slimming injection for dissolving fat |
| CN110200990A (en) * | 2019-07-08 | 2019-09-06 | 陶鹤 | A kind of drug and preparation method for reducing RE and damaging tumor radiotherapy to patient |
| CN113181238A (en) * | 2021-06-08 | 2021-07-30 | 柯樱雪 | Injection for acupoint injection therapy for treating myopia |
| CN113456806A (en) * | 2021-08-04 | 2021-10-01 | 常慧楠 | I-type collagen suspension medicament and preparation method thereof |
-
2021
- 2021-10-13 CN CN202111194181.2A patent/CN113730650B/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1650919A (en) * | 2004-12-10 | 2005-08-10 | 山东齐都药业有限公司 | Prescription of Chinese medicine compound preparation, its preparation method and use |
| CN102940623A (en) * | 2012-12-05 | 2013-02-27 | 罗诚 | Medicinal composition of levocarnitine compound |
| CA2967699A1 (en) * | 2014-11-13 | 2016-05-19 | Merz Pharma Gmbh & Co. Kgaa | Dermal filler based on crosslinked hyaluronic acid and carboxymethyl cellulose lubricant |
| WO2017037593A2 (en) * | 2015-08-28 | 2017-03-09 | 康霈生技股份有限公司 | Pharmaceutical composition used for reducing localised fat and use of pharmaceutical composition |
| CN110604834A (en) * | 2019-03-14 | 2019-12-24 | 上海欧邦医疗管理有限公司 | Application of hydro-acupuncture liquid medicine in preparation of medicine for treating lymph stasis and obstruction areas |
Non-Patent Citations (2)
| Title |
|---|
| Effect of increased fat availability on metabolism and exercise capacity;JOHN A. HAWLEY等;《MEDICINE & SCIENCE IN SPORTS & EXERCISE》;20021231;第1485-1491页 * |
| Gastrodin Ameliorates Oxidative Stress and Proinflammatory Response in Nonalcoholic Fatty Liver Disease through the AMPK/Nrf2 Pathway;Li-Li Qu等;《Phytother. Res. 》;20151204;第30卷;第402-411页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113730650A (en) | 2021-12-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11878034B2 (en) | Vitamin supplement compositions for injection | |
| US8883131B2 (en) | Composition for the treatment of hair loss and baldness | |
| CN101518508B (en) | Beautifying health composition and facial mask | |
| CN101199773A (en) | Compound essential oil of refreshing thinker | |
| CN101829043B (en) | Traditional Chinese medicine facial mask for improving sleep quality and preparation method thereof | |
| CN113730650B (en) | Carbohydrate-lysozyme composition and preparation method and application thereof | |
| CN109481351B (en) | Preparation method of compound plant meridian conditioning oil | |
| CN111773114A (en) | Negative ion crystal eye mask | |
| CN103417966B (en) | Hydrochloric acid aminolevulinic acid liniment and preparation technology thereof | |
| CN101716306A (en) | Medicated wine for dispelling speckles and whitening face | |
| CN103027926A (en) | Pharmaceutical composition used for nutritional supplement and preparation method of oral liquid thereof | |
| CN104001157A (en) | Compound preparation for preventing and treating osteoporosis and preparation method thereof | |
| CN102319355B (en) | Chinese medicinal formula for treating hyperactivity and preparation method for pills thereof | |
| CN115282137B (en) | External liniment nursing composition and preparation method thereof | |
| Knoll et al. | Illustrated Atlas of Esthetic Mesotherapy | |
| CN107723183A (en) | A kind of Suillus albidipes (Peck) Sing small-molecular peptides compounding wine and preparation method thereof | |
| CN101829039B (en) | Traditional Chinese medicine facial mask for relieving head and neck pains and preparation method thereof | |
| US11986508B1 (en) | Nutritional and cosmetic product, system and method for use | |
| CN101279007A (en) | Chinese medicine for curing aconuresis | |
| CN105456567A (en) | Traditional Chinese medicine composition for treating kidney-qi deficiency type idiopathic dwarfness | |
| CN115252663A (en) | Composition for rapidly regulating vegetative nerve and preparation method and application thereof | |
| SI26154A (en) | Composition comprising dioscorea batatas | |
| CN118121520A (en) | Traditional Tibetan medicine hair tonic for accelerating regeneration, preparation and use methods | |
| CN102895643B (en) | Composition for tonifying qi, arresting sperm, nourishing qi, nourishing blood and strengthening waist and knees | |
| CN103040957B (en) | Hair growth-promoting solution |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |